ClinicalTrials.Veeva

Menu

Midodrine During Recovery From Septic Shock

Northwell Health logo

Northwell Health

Status and phase

Withdrawn
Phase 4

Conditions

Hypotension
Shock, Septic
Sepsis

Treatments

Drug: placebo
Drug: Midodrine

Study type

Interventional

Funder types

Other

Identifiers

NCT02771158
temp-1187

Details and patient eligibility

About

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • admitted to intensive care unit
  • diagnosis of septic shock on intravenous vasopressors
  • stable/decreasing doses of intravenous vasopressors
  • stable/improving organ function

Exclusion criteria

  • allergy to midodrine
  • multiple intravenous vasopressors
  • increasing intravenous vasopressor requirements
  • worsening organ dysfunction
  • severe bradycardia

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups, including a placebo group

midodrine
Experimental group
Description:
randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
Treatment:
Drug: Midodrine
placebo
Placebo Comparator group
Description:
randomization to placebo control
Treatment:
Drug: placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems